Table 3 Correlation between smoking and clinical factors
From: The effect of smoking on biological change of recurrent breast cancer
| Parameters | Smoking | p value | |
|---|---|---|---|
| No-smoker (n = 36) | Smoker (n = 14) | ||
| Age at operation (years old) | |||
| ≤ 60 | 19 (52.8%) | 7 (50.0%) | 0.863 |
| > 60 | 17 (47.2%) | 7 (50.0%) | |
| Tumor size (mm) | |||
| ≤ 21.8 | 16 (44.4%) | 9 (64.3%) | 0.216 |
| > 21.8 | 20 (55.6%) | 5 (35.7%) | |
| Lymph node metastasis | |||
| Negative | 31 (86.1%) | 12 (85.7%) | 0.972 |
| Positive | 5 (13.9%) | 2 (14.3%) | |
| Estrogen receptor (ER) of primary tumor | |||
| Negative | 10 (27.8%) | 3 (21.4%) | 0.654 |
| Positive | 26 (72.2%) | 11 (78.6%) | |
| Progesterone receptor (PgR) of primary tumor | |||
| Negative | 12 (33.3%) | 3 (21.4%) | 0.420 |
| Positive | 24 (66.7%) | 11 (78.6%) | |
| HER2 of primary tumor | |||
| Negative | 35 (97.2%) | 13 (92.9%) | 0.490 |
| Positive | 1 (2.8%) | 1 (7.1%) | |
| Ki67 of primary tumor | |||
| ≤ 14% | 15 (41.7%) | 4 (28.6%) | 0.402 |
| > 14% | 21 (58.3%) | 10 (71.4%) | |
| Intrinsic subtype HRBC | |||
| No | 10 (27.8%) | 2 (14.3%) | 0.326 |
| Yes | 26 (72.2%) | 12 (85.7%) | |
| Intrinsic subtype HER2BC | |||
| No | 35 (97.2%) | 13 (92.9%) | 0.490 |
| Yes | 1 (2.8%) | 1 (7.1%) | |
| Intrinsic subtype TNBC | |||
| No | 27 (75.0%) | 13 (92.9%) | 0.163 |
| Yes | 9 (25.0%) | 1 (7.1%) | |
| Chemotherapy after surgery | |||
| No | 26 (72.2%) | 11 (78.6%) | 0.654 |
| Yes | 10 (27.8%) | 3 (21.4%) | |
| Endocrine therapy after surgery | |||
| No | 11 (30.6%) | 3 (21.4%) | 0.529 |
| Yes | 25 (69.4%) | 11 (78.6%) | |
| Radiation therapy after surgery | |||
| No | 30 (83.3%) | 9 (64.3%) | 0.150 |
| Yes | 6 (16.7%) | 5 (35.7%) | |
| Trastuzumab after surgery | |||
| No | 35 (97.2%) | 14 (100.0%) | 0.538 |
| Yes | 1 (2.8%) | 0 (0.0%) | |
| No-treatment after surgery | |||
| No | 32 (88.9%) | 12 (85.7%) | 0.762 |
| Yes | 4 (11.1%) | 2 (14.3%) | |
| Age at recurrence (years old) | |||
| ≤ 62 | 20 (55.6%) | 6 (42.9%) | 0.430 |
| > 62 | 16 (44.4%) | 8 (57.1%) | |
| Recurrence site biopsied | |||
| Local, regional lymph node | 31 (86.1%) | 14 (100.0%) | 0.108 |
| Distant metastasis | 5 (13.9%) | 0 (0.0%) | |
| Change of ER in recurrence | |||
| Negative conversion | 2 (5.6%) | 1 (7.1%) | 0.836 |
| The other | 34 (94.4%) | 13 (92.9%) | |
| Change of PgR in recurrence | |||
| Negative conversion | 9 (25.0%) | 6 (42.9%) | 0.224 |
| No change | 27 (75.0%) | 8 (57.1%) | |
| Change of HER2 in recurrence | |||
| Positive conversion | 2 (5.6%) | 4 (28.6%) | 0.024 |
| No change | 34 (94.4%) | 10 (71.4%) | |
| Change of intrinsic subtype in recurrent tumor | |||
| No | 32 (88.9%) | 13 (92.9%) | 0.682 |
| Yes | 4 (11.1%) | 1 (7.1%) | |
| Disease free survival | |||
| ≤ 792 | 19 (52.8%) | 6 (42.9%) | 0.538 |
| > 792 | 17 (47.2%) | 8 (57.1%) | |
